184 related articles for article (PubMed ID: 36867078)
1. Phenotypic subtypes predict outcomes in colorectal cancer.
Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
[TBL] [Abstract][Full Text] [Related]
2. Consensus molecular subtype classification of colorectal adenomas.
Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
[TBL] [Abstract][Full Text] [Related]
3. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)].
Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F
Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988
[TBL] [Abstract][Full Text] [Related]
4. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
[TBL] [Abstract][Full Text] [Related]
5. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
[TBL] [Abstract][Full Text] [Related]
6. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
[TBL] [Abstract][Full Text] [Related]
7. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
[TBL] [Abstract][Full Text] [Related]
9. Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer.
Dunne PD; O'Reilly PG; Coleman HG; Gray RT; Longley DB; Johnston PG; Salto-Tellez M; Lawler M; McArt DG
Oncotarget; 2016 Jun; 7(24):36632-36644. PubMed ID: 27153559
[TBL] [Abstract][Full Text] [Related]
10. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
[TBL] [Abstract][Full Text] [Related]
11. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
[TBL] [Abstract][Full Text] [Related]
12. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy.
Becht E; de Reyniès A; Giraldo NA; Pilati C; Buttard B; Lacroix L; Selves J; Sautès-Fridman C; Laurent-Puig P; Fridman WH
Clin Cancer Res; 2016 Aug; 22(16):4057-66. PubMed ID: 26994146
[TBL] [Abstract][Full Text] [Related]
13. The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
Marisa L; Svrcek M; Collura A; Becht E; Cervera P; Wanherdrick K; Buhard O; Goloudina A; Jonchère V; Selves J; Milano G; Guenot D; Cohen R; Colas C; Laurent-Puig P; Olschwang S; Lefèvre JH; Parc Y; Boige V; Lepage C; André T; Fléjou JF; Dérangère V; Ghiringhelli F; de Reynies A; Duval A
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922790
[TBL] [Abstract][Full Text] [Related]
14. Functional proteomics of colon cancer Consensus Molecular Subtypes.
Feliu J; Gámez-Pozo A; Martínez-Pérez D; Pérez-Wert P; Matamala-Luengo D; Viñal D; Kunz L; López-Vacas R; Dittmann A; Rodríguez-Salas N; Custodio A; Fresno Vara JÁ; Trilla-Fuertes L
Br J Cancer; 2024 Jun; 130(10):1670-1678. PubMed ID: 38486123
[TBL] [Abstract][Full Text] [Related]
15. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
[TBL] [Abstract][Full Text] [Related]
16. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.
Chang K; Willis JA; Reumers J; Taggart MW; San Lucas FA; Thirumurthi S; Kanth P; Delker DA; Hagedorn CH; Lynch PM; Ellis LM; Hawk ET; Scheet PA; Kopetz S; Arts J; Guinney J; Dienstmann R; Vilar E
Ann Oncol; 2018 Oct; 29(10):2061-2067. PubMed ID: 30412224
[TBL] [Abstract][Full Text] [Related]
17. Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials.
Fontana E; Eason K; Cervantes A; Salazar R; Sadanandam A
Ann Oncol; 2019 Apr; 30(4):520-527. PubMed ID: 30796810
[TBL] [Abstract][Full Text] [Related]
18. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.
Perez-Villamil B; Romera-Lopez A; Hernandez-Prieto S; Lopez-Campos G; Calles A; Lopez-Asenjo JA; Sanz-Ortega J; Fernandez-Perez C; Sastre J; Alfonso R; Caldes T; Martin-Sanchez F; Diaz-Rubio E
BMC Cancer; 2012 Jun; 12():260. PubMed ID: 22712570
[TBL] [Abstract][Full Text] [Related]
19. Investigation of colorectal cancer in accordance with consensus molecular subtype classification.
Sawayama H; Miyamoto Y; Ogawa K; Yoshida N; Baba H
Ann Gastroenterol Surg; 2020 Sep; 4(5):528-539. PubMed ID: 33005848
[TBL] [Abstract][Full Text] [Related]
20. Refining colorectal cancer classification and clinical stratification through a single-cell atlas.
Khaliq AM; Erdogan C; Kurt Z; Turgut SS; Grunvald MW; Rand T; Khare S; Borgia JA; Hayden DM; Pappas SG; Govekar HR; Kam AE; Reiser J; Turaga K; Radovich M; Zang Y; Qiu Y; Liu Y; Fishel ML; Turk A; Gupta V; Al-Sabti R; Subramanian J; Kuzel TM; Sadanandam A; Waldron L; Hussain A; Saleem M; El-Rayes B; Salahudeen AA; Masood A
Genome Biol; 2022 May; 23(1):113. PubMed ID: 35538548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
